CFTR Folding Consortium: methods available for studies of CFTR folding and correction.

Kathryn W. Peters, Tsukasa Okiyoneda, William E. Balch, Ineke Braakman, Jeffrey L. Brodsky, William B. Guggino, Christopher M. Penland, Harvey B. Pollard, Eric J. Sorscher, William R. Skach, Philip J. Thomas, Gergely L. Lukacs, Raymond A. Frizzell

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The CFTR Folding Consortium (CFC) was formed in 2004 under the auspices of the Cystic Fibrosis Foundation and its drug discovery and development affiliate, CFF Therapeutics. A primary goal of the CFC is the development and distribution of reagents and assay methods designed to better understand the mechanistic basis of mutant CFTR misfolding and to identify targets whose manipulation may correct CFTR folding defects. As such, reagents available from the CFC primarily target wild-type CFTR NBD1 and its common variant, F508del, and they include antibodies, cell lines, constructs, and proteins. These reagents are summarized here, and two protocols are described for the detection of cell surface CFTR: (a) an assay of the density of expressed HA-tagged CFTR by ELISA and (b) the generation and use of an antibody to CFTR's first extracellular loop for the detection of endogenous CFTR. Finally, we highlight a systematic collection of assays, the CFC Roadmap, which is being used to assess the cellular locus and mechanism of mutant CFTR correction. The Roadmap queries CFTR structure-function relations at levels ranging from purified protein to well-differentiated human airway primary cultures.

Original languageEnglish (US)
Pages (from-to)335-353
Number of pages19
JournalMethods in molecular biology (Clifton, N.J.)
Volume742
DOIs
StatePublished - 2011

Fingerprint

Antibodies
Drug Discovery
Cystic Fibrosis
Proteins
Enzyme-Linked Immunosorbent Assay
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Peters, K. W., Okiyoneda, T., Balch, W. E., Braakman, I., Brodsky, J. L., Guggino, W. B., ... Frizzell, R. A. (2011). CFTR Folding Consortium: methods available for studies of CFTR folding and correction. Methods in molecular biology (Clifton, N.J.), 742, 335-353. https://doi.org/10.1007/978-1-61779-120-8_20

CFTR Folding Consortium : methods available for studies of CFTR folding and correction. / Peters, Kathryn W.; Okiyoneda, Tsukasa; Balch, William E.; Braakman, Ineke; Brodsky, Jeffrey L.; Guggino, William B.; Penland, Christopher M.; Pollard, Harvey B.; Sorscher, Eric J.; Skach, William R.; Thomas, Philip J.; Lukacs, Gergely L.; Frizzell, Raymond A.

In: Methods in molecular biology (Clifton, N.J.), Vol. 742, 2011, p. 335-353.

Research output: Contribution to journalArticle

Peters, KW, Okiyoneda, T, Balch, WE, Braakman, I, Brodsky, JL, Guggino, WB, Penland, CM, Pollard, HB, Sorscher, EJ, Skach, WR, Thomas, PJ, Lukacs, GL & Frizzell, RA 2011, 'CFTR Folding Consortium: methods available for studies of CFTR folding and correction.', Methods in molecular biology (Clifton, N.J.), vol. 742, pp. 335-353. https://doi.org/10.1007/978-1-61779-120-8_20
Peters, Kathryn W. ; Okiyoneda, Tsukasa ; Balch, William E. ; Braakman, Ineke ; Brodsky, Jeffrey L. ; Guggino, William B. ; Penland, Christopher M. ; Pollard, Harvey B. ; Sorscher, Eric J. ; Skach, William R. ; Thomas, Philip J. ; Lukacs, Gergely L. ; Frizzell, Raymond A. / CFTR Folding Consortium : methods available for studies of CFTR folding and correction. In: Methods in molecular biology (Clifton, N.J.). 2011 ; Vol. 742. pp. 335-353.
@article{f4b867f8a1854d4f8c53eb873131b51b,
title = "CFTR Folding Consortium: methods available for studies of CFTR folding and correction.",
abstract = "The CFTR Folding Consortium (CFC) was formed in 2004 under the auspices of the Cystic Fibrosis Foundation and its drug discovery and development affiliate, CFF Therapeutics. A primary goal of the CFC is the development and distribution of reagents and assay methods designed to better understand the mechanistic basis of mutant CFTR misfolding and to identify targets whose manipulation may correct CFTR folding defects. As such, reagents available from the CFC primarily target wild-type CFTR NBD1 and its common variant, F508del, and they include antibodies, cell lines, constructs, and proteins. These reagents are summarized here, and two protocols are described for the detection of cell surface CFTR: (a) an assay of the density of expressed HA-tagged CFTR by ELISA and (b) the generation and use of an antibody to CFTR's first extracellular loop for the detection of endogenous CFTR. Finally, we highlight a systematic collection of assays, the CFC Roadmap, which is being used to assess the cellular locus and mechanism of mutant CFTR correction. The Roadmap queries CFTR structure-function relations at levels ranging from purified protein to well-differentiated human airway primary cultures.",
author = "Peters, {Kathryn W.} and Tsukasa Okiyoneda and Balch, {William E.} and Ineke Braakman and Brodsky, {Jeffrey L.} and Guggino, {William B.} and Penland, {Christopher M.} and Pollard, {Harvey B.} and Sorscher, {Eric J.} and Skach, {William R.} and Thomas, {Philip J.} and Lukacs, {Gergely L.} and Frizzell, {Raymond A.}",
year = "2011",
doi = "10.1007/978-1-61779-120-8_20",
language = "English (US)",
volume = "742",
pages = "335--353",
journal = "Methods in molecular biology (Clifton, N.J.)",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - CFTR Folding Consortium

T2 - methods available for studies of CFTR folding and correction.

AU - Peters, Kathryn W.

AU - Okiyoneda, Tsukasa

AU - Balch, William E.

AU - Braakman, Ineke

AU - Brodsky, Jeffrey L.

AU - Guggino, William B.

AU - Penland, Christopher M.

AU - Pollard, Harvey B.

AU - Sorscher, Eric J.

AU - Skach, William R.

AU - Thomas, Philip J.

AU - Lukacs, Gergely L.

AU - Frizzell, Raymond A.

PY - 2011

Y1 - 2011

N2 - The CFTR Folding Consortium (CFC) was formed in 2004 under the auspices of the Cystic Fibrosis Foundation and its drug discovery and development affiliate, CFF Therapeutics. A primary goal of the CFC is the development and distribution of reagents and assay methods designed to better understand the mechanistic basis of mutant CFTR misfolding and to identify targets whose manipulation may correct CFTR folding defects. As such, reagents available from the CFC primarily target wild-type CFTR NBD1 and its common variant, F508del, and they include antibodies, cell lines, constructs, and proteins. These reagents are summarized here, and two protocols are described for the detection of cell surface CFTR: (a) an assay of the density of expressed HA-tagged CFTR by ELISA and (b) the generation and use of an antibody to CFTR's first extracellular loop for the detection of endogenous CFTR. Finally, we highlight a systematic collection of assays, the CFC Roadmap, which is being used to assess the cellular locus and mechanism of mutant CFTR correction. The Roadmap queries CFTR structure-function relations at levels ranging from purified protein to well-differentiated human airway primary cultures.

AB - The CFTR Folding Consortium (CFC) was formed in 2004 under the auspices of the Cystic Fibrosis Foundation and its drug discovery and development affiliate, CFF Therapeutics. A primary goal of the CFC is the development and distribution of reagents and assay methods designed to better understand the mechanistic basis of mutant CFTR misfolding and to identify targets whose manipulation may correct CFTR folding defects. As such, reagents available from the CFC primarily target wild-type CFTR NBD1 and its common variant, F508del, and they include antibodies, cell lines, constructs, and proteins. These reagents are summarized here, and two protocols are described for the detection of cell surface CFTR: (a) an assay of the density of expressed HA-tagged CFTR by ELISA and (b) the generation and use of an antibody to CFTR's first extracellular loop for the detection of endogenous CFTR. Finally, we highlight a systematic collection of assays, the CFC Roadmap, which is being used to assess the cellular locus and mechanism of mutant CFTR correction. The Roadmap queries CFTR structure-function relations at levels ranging from purified protein to well-differentiated human airway primary cultures.

UR - http://www.scopus.com/inward/record.url?scp=80052541318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052541318&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-120-8_20

DO - 10.1007/978-1-61779-120-8_20

M3 - Article

C2 - 21547742

AN - SCOPUS:80052541318

VL - 742

SP - 335

EP - 353

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

SN - 1064-3745

ER -